Overall survival (OS)
The CR rate after initial treatment of all 298 GTN patients approached 88.4% and the 5-year OS rate of all 298 GTN patients was 98.7%, with a median follow-up time of six years (range: 62–82 months; IQR: 20 months) (Figures 2, 3). The CR rate after initial treatment in ultra-high-risk patients approached 11.1% and the 5-year OS rate was 77.8% (n=18). The CR rate after initial treatment in ultra-high-risk patients with liver or brain metastases approached 0% and the 5-year OS rate was 81.8% (n=11).
Survival time was significantly shorter among patients with than in those without brain and liver metastases (P <0.01, log-rank test; Figures 2, 3).